amphetamine has been researched along with Memory Disorders in 21 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Memory Disorders: Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats." | 5.48 | Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. ( Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y, 2018) |
| "We used the passive avoidance test and acute amphetamine administration in aging gammasynuclein knock-out mice." | 3.88 | The Dopaminergic Dysfunction and Altered Working Memory Performance of Aging Mice Lacking Gamma-synuclein Gene. ( Aliev, G; Fisenko, VP; Kokhan, TYG; Kokhan, VS; Samsonova, AN; Ustyugov, AA, 2018) |
| "Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats." | 1.48 | Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. ( Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y, 2018) |
| "PWZ-029 did not affect recognition memory deficits in social novelty discrimination procedure." | 1.42 | Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion. ( Biawat, P; Cook, JM; Joksimović, S; Marković, B; Savić, MM; Stanković, T; Timić Stamenić, T, 2015) |
| "Candesartan (CDS) is an AT1 receptor antagonist with potential neuroprotective properties." | 1.42 | Antimanic-like activity of candesartan in mice: Possible involvement of antioxidant, anti-inflammatory and neurotrophic mechanisms. ( Berk, M; Budni, J; Carvalho, AF; Cavalcante, LM; de Lucena, DF; de Sousa, FC; de Souza Gomes, JA; de Souza, GC; Macêdo, D; Quevedo, J, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Di Capua, A | 1 |
| Reale, A | 1 |
| Paolino, M | 1 |
| Chemi, G | 1 |
| Brogi, S | 1 |
| Cappelli, A | 1 |
| Giorgi, G | 1 |
| Grande, F | 1 |
| Di Cesare Mannelli, L | 1 |
| Ghelardini, C | 1 |
| Matucci, R | 1 |
| Garofalo, A | 1 |
| Anzini, M | 1 |
| Arab, AO | 1 |
| Alasmari, F | 1 |
| Albaker, AB | 1 |
| Alhazmi, HA | 1 |
| Alameen, AA | 1 |
| Alagail, NM | 1 |
| Alwaeli, SA | 1 |
| Rizwan Ahamad, S | 1 |
| AlAsmari, AF | 1 |
| AlSharari, SD | 1 |
| Tufvesson-Alm, M | 1 |
| Imbeault, S | 1 |
| Liu, XC | 1 |
| Zheng, Y | 1 |
| Faka, A | 1 |
| Choi, DS | 1 |
| Schwieler, L | 1 |
| Engberg, G | 1 |
| Erhardt, S | 1 |
| Koh, MT | 2 |
| Shao, Y | 2 |
| Rosenzweig-Lipson, S | 1 |
| Gallagher, M | 1 |
| Mishra, A | 1 |
| Mishra, AK | 1 |
| Jha, S | 1 |
| Kokhan, VS | 1 |
| Kokhan, TYG | 1 |
| Samsonova, AN | 1 |
| Fisenko, VP | 1 |
| Ustyugov, AA | 1 |
| Aliev, G | 1 |
| Loiodice, S | 1 |
| Wing Young, H | 1 |
| Rion, B | 1 |
| Méot, B | 1 |
| Montagne, P | 1 |
| Denibaud, AS | 1 |
| Viel, R | 1 |
| Drieu La Rochelle, C | 1 |
| Timić Stamenić, T | 1 |
| Joksimović, S | 1 |
| Biawat, P | 1 |
| Stanković, T | 1 |
| Marković, B | 1 |
| Cook, JM | 1 |
| Savić, MM | 1 |
| de Souza Gomes, JA | 1 |
| de Souza, GC | 1 |
| Berk, M | 1 |
| Cavalcante, LM | 1 |
| de Sousa, FC | 1 |
| Budni, J | 1 |
| de Lucena, DF | 1 |
| Quevedo, J | 1 |
| Carvalho, AF | 1 |
| Macêdo, D | 1 |
| Sherwood, A | 1 |
| Smith, DR | 1 |
| Marszalek-Grabska, M | 1 |
| Gibula-Bruzda, E | 1 |
| Jenda, M | 1 |
| Gawel, K | 1 |
| Kotlinska, JH | 1 |
| Woolley, ML | 1 |
| Waters, KA | 1 |
| Reavill, C | 1 |
| Bull, S | 1 |
| Lacroix, LP | 1 |
| Martyn, AJ | 1 |
| Hutcheson, DM | 1 |
| Valerio, E | 1 |
| Bate, S | 1 |
| Jones, DN | 1 |
| Dawson, LA | 1 |
| Moeller, FG | 1 |
| Steinberg, JL | 1 |
| Schmitz, JM | 1 |
| Ma, L | 1 |
| Liu, S | 1 |
| Kjome, KL | 1 |
| Rathnayaka, N | 1 |
| Kramer, LA | 1 |
| Narayana, PA | 1 |
| López-Téllez, JF | 1 |
| López-Aranda, MF | 1 |
| Navarro-Lobato, I | 1 |
| Masmudi-Martín, M | 1 |
| Montañez, EM | 1 |
| Calvo, EB | 1 |
| Khan, ZU | 1 |
| Papaleo, F | 1 |
| Yang, F | 1 |
| Garcia, S | 1 |
| Chen, J | 1 |
| Lu, B | 1 |
| Crawley, JN | 1 |
| Weinberger, DR | 1 |
| Won, H | 1 |
| Mah, W | 1 |
| Kim, E | 2 |
| Kim, JW | 1 |
| Hahm, EK | 1 |
| Kim, MH | 1 |
| Cho, S | 1 |
| Kim, J | 1 |
| Jang, H | 1 |
| Cho, SC | 1 |
| Kim, BN | 1 |
| Shin, MS | 1 |
| Seo, J | 1 |
| Jeong, J | 1 |
| Choi, SY | 1 |
| Kim, D | 1 |
| Kang, C | 1 |
| Sumowski, JF | 1 |
| Chiaravalloti, N | 1 |
| Erlanger, D | 1 |
| Kaushik, T | 1 |
| Benedict, RH | 1 |
| DeLuca, J | 1 |
| Sanday, L | 1 |
| Patti, CL | 1 |
| Zanin, KA | 1 |
| Tufik, S | 1 |
| Frussa-Filho, R | 1 |
| Daumann, J | 1 |
| Fischermann, T | 1 |
| Heekeren, K | 1 |
| Henke, K | 1 |
| Thron, A | 1 |
| Gouzoulis-Mayfrank, E | 1 |
| Jarvik, ME | 1 |
| Gritz, ER | 1 |
| Schneider, NG | 1 |
| Jones, HB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dysbindin-antipsychotics Psychophamarcogenetics: a Mouse-human Translational Study Towards Personalized Healthcare in Bipolar Disorders[NCT06167577] | 150 participants (Actual) | Observational | 2018-11-08 | Completed | |||
| Candidate Gene Screening for 6-14 Year Old Patients With ADHD (Attention Deficit/ Hyperactivity Disorder)[NCT03018574] | 100 participants (Actual) | Observational | 2016-05-31 | Completed | |||
| Stimulation of Parieto-hippocampal Connectivity in Patients With Major Depressive Disorder[NCT04081519] | 53 participants (Actual) | Interventional | 2016-08-02 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amphetamine and Memory Disorders
| Article | Year |
|---|---|
Drugs and memory disorders in human aging.
Topics: Adolescent; Adult; Aged; Aging; Amphetamine; Anticonvulsants; Antidepressive Agents; Arousal; Caffei | 1972 |
2 trials available for amphetamine and Memory Disorders
| Article | Year |
|---|---|
Working memory fMRI activation in cocaine-dependent subjects: association with treatment response.
Topics: Adult; Amphetamine; Analysis of Variance; Benzhydryl Compounds; Brain; Brain Mapping; Carbidopa; Cen | 2010 |
L-amphetamine improves memory in MS patients with objective memory impairment.
Topics: Adult; Amphetamine; Double-Blind Method; Female; Humans; Male; Memory; Memory Disorders; Middle Aged | 2011 |
18 other studies available for amphetamine and Memory Disorders
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of 7-substituted 4-phenyl-6H-imidazo[1,5-a]thieno[3,2-f] [1,4]diazepines as safe anxiolytic agents.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Binding Sites; Drug Design; Locomoti | 2020 |
Clavulanic Acid Improves Memory Dysfunction and Anxiety Behaviors through Upregulating Glutamatergic Transporters in the Nucleus Accumbens of Mice Repeatedly Exposed to Khat Extract.
Topics: Amphetamine; Animals; Anxiety; Catha; Clavulanic Acid; Memory Disorders; Mice; Nucleus Accumbens; Ra | 2023 |
Repeated administration of LPS exaggerates amphetamine-induced locomotor response and causes learning deficits in mice.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Drug Administration Schedule; Drug Synergis | 2020 |
Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Cognition Disorders; Disease Models, Animal | 2018 |
Effect of traditional medicine brahmi vati and bacoside A-rich fraction of Bacopa monnieri on acute pentylenetetrzole-induced seizures, amphetamine-induced model of schizophrenia, and scopolamine-induced memory loss in laboratory animals.
Topics: Acetylcholinesterase; Amnesia; Amphetamine; Animals; Animals, Laboratory; Antioxidants; Bacopa; Brai | 2018 |
The Dopaminergic Dysfunction and Altered Working Memory Performance of Aging Mice Lacking Gamma-synuclein Gene.
Topics: Aging; Amphetamine; Animals; Avoidance Learning; Disease Models, Animal; Dopamine; Dopamine Agents; | 2018 |
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; | 2019 |
Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion.
Topics: Amphetamine; Animals; Behavior, Animal; Benzodiazepines; Cognition Disorders; Dizocilpine Maleate; H | 2015 |
Antimanic-like activity of candesartan in mice: Possible involvement of antioxidant, anti-inflammatory and neurotrophic mechanisms.
Topics: Amphetamine; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antimanic A | 2015 |
Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia.
Topics: Amphetamine; Animals; Conditioning, Classical; Disease Models, Animal; Fear; Hippocampus; Interneuro | 2016 |
Memantine improves memory impairment and depressive-like behavior induced by amphetamine withdrawal in rats.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Antidepressive Agents; Central Nervous System S | 2016 |
Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat.
Topics: Acetamides; Acetylcholine; Amphetamine; Animals; Behavior, Animal; Cognition; Disease Models, Animal | 2008 |
Prefrontal inositol triphosphate is molecular correlate of working memory in nonhuman primates.
Topics: Amphetamine; Animals; Antipsychotic Agents; Calcium; Calcium Signaling; Central Nervous System Stimu | 2010 |
Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways.
Topics: Action Potentials; Amphetamine; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Carrier | 2012 |
GIT1 is associated with ADHD in humans and ADHD-like behaviors in mice.
Topics: Adaptor Proteins, Signal Transducing; Amphetamine; Animals; Attention Deficit Disorder with Hyperact | 2011 |
Amphetamine-induced memory impairment in a discriminative avoidance task is state-dependent in mice.
Topics: Amphetamine; Animals; Avoidance Learning; Discrimination Learning; Male; Memory Disorders; Mice | 2013 |
Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users.
Topics: Adult; Amphetamine; Brain Mapping; Cannabis; Female; Hallucinogens; Hippocampus; Humans; Magnetic Re | 2005 |
The effects of sensual drugs on behavior: clues to the function of the brain.
Topics: Alcoholic Intoxication; Amphetamine; Barbiturates; Brain; Cannabis; Cocaine; Emotions; Female; Hallu | 1974 |